Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Vistakon Pharmaceuticals
Vistakon Pharmaceuticals
Industry · 13 registered clinical trials.
Status
Trial
Phase
Started
Completed
Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma, Ocular Hypertension
Phase 2
2009-10-01
Completed
Safety and Efficacy Study of a Eye Drop for Eye Allergy
Allergic Conjunctivitis
Phase 3
2009-04-01
Completed
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
Allergic Conjunctivitis
Phase 3
2009-04-01
Completed
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
Open-angle Glaucoma, Ocular Hypertension
—
2009-01-01
Completed
Safety and Efficacy of a Glaucoma Drug Delivery System
Glaucoma, Open-Angle, Ocular Hypertension
Phase 2
2008-12-01
Completed
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open Angle, Ocular Hypertension
Phase 4
2008-11-01
Completed
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
Allergic Conjunctivitis
Phase 3
2007-10-01
Completed
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Con
Allergic Conjunctivitis
Phase 3
2007-02-01
Completed
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
Allergic Conjunctivitis
Phase 3
2007-01-01
Completed
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
Allergic Conjunctivitis
Phase 3
2006-08-01
Completed
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
Allergic Conjunctivitis
Phase 3
2005-10-01
Completed
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
Allergic Conjunctivitis
Phase 3
2005-10-01
Completed
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Phase 3
2005-09-01